echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Bayer/Merxton guanylate cyclase agonist approved in the EU for the treatment of heart failure

    Bayer/Merxton guanylate cyclase agonist approved in the EU for the treatment of heart failure

    • Last Update: 2021-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article Source: Immediate Medicine News

    On July 21st, Merck (MSD) and Bayer (Bayer) jointly announced that the European Commission (EC) has approved the listing of its soluble guanylate cyclase (sGC) stimulant Verquvo (vericiguat) for the treatment of adults with reduced ejection fraction Patients with symptomatic chronic heart failure who have stabilized after a recent decompensated event that required intravenous (IV) therapy


    Reduced ejection fraction (HFrEF) heart failure, formerly known as systolic heart failure, is characterized by impaired ability of the heart to eject blood adequately during its contraction phase


    Heart failure is related to nitric oxide (NO) synthesis disorder and decreased sGC activity


    Verquvo was jointly developed by Merck and Bayer.


    Note: The original text has been deleted

    Reference materials:

    [1] VERQUVO® (vericiguat) Approved in the European Union.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.